Nihan Izat

Nihan Izat

Auto-generated profile, based on publicly available information

Nihan Izat

Centre for Applied Pharmacokinetic Research, The University of Manchester Manchester UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
TGTugba Gulsun
Tugba Gulsun
MIMurat Inal
Murat Inal
YAYagmur Akdag
Yagmur Akdag
NINihan Izat
Nihan Izat
LOLevent Oner
Levent Oner
SSSelma Sahin
Selma Sahin

11 June 2020 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
TGTugba Gulsun
Tugba Gulsun
YAYagmur Akdag
Yagmur Akdag
NINihan Izat
Nihan Izat
MCMeltem Cetin
Meltem Cetin
LÖLevent Öner
Levent Öner
SSSelma Sahin
Selma Sahin
Diabetes is characterized by chronic hyperglycemia. Although metformin hydrochloride (MHCl)- and glyburide (GLB)-containing conventional tablets are available in the market and used to treat diabetes, orally disintegrating tablets (ODTs) containing the combination of these drugs are not commercially available. Therefore, the aim of this study was to prepare ODTs containing MHCl and GLB by direct-compression (DC-ODTs) and freeze-drying (FD-ODTs) methods. Physical properties of the powder mixture of DC-ODT formulation were determined (Angle of repose: 37.18 ± 1.27°; compressibility index: 20.31 ± 1.06%; Hausner ratio:1.25 ± 0.03). Its moisture content was 0.3 ± 0.09%. The hardness values and the disintegration times for DC-ODTs and FD-ODTs were 221.60 ± 40.82 N and 66.54 ± 2.68 N, and 80 s and 30 s, respectively. Friability values were 0.24% for DC-ODTs and 0.38% for FD-ODTs. In uniformity-of-mass for single-dose-preparations test, the average weight was 684.38 ± 1.97mg for DC-ODTs and 342.93 ± 2.4mg for FD-ODTs, with less than 5% deviation for all 20 tablets. Water-absorption ratio for DC-ODTs was 1.30 ± 0.05. More than 90% of MHCl and GLB were dissolved within 5 min in both DC-ODTs and FD-ODTs. Although Caco-2 permeability of MHCl was influenced by the ODTs, GLB permeability was not. These results indicated that MHCl- and GLB-containing ODTs may be used as promising formulations for the treatment of diabetes.

26 September 2023 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
NINihan Izat
Nihan Izat
JBJayaprakasam Bolleddula
Jayaprakasam Bolleddula
AAArmina Abbasi
Armina Abbasi
LCLionel Cheruzel
Lionel Cheruzel
RJRobert S. Jones
Robert S. Jones
DSDaniel Scotcher
Daniel Scotcher
Underestimation of AO-mediated clearance by current in vitro assays leads to uncertainty in human dose projections, thereby reducing the likelihood of success in drug development. In the present study we first evaluated the current drug development practices for AO substrates. Next, the overall predictive performance of in vitro-in vivo extrapolation (IVIVE) of unbound hepatic intrinsic clearance (CLint,u) and unbound hepatic intrinsic clearance by AO (CLint,u,AO) was assessed using a comprehensive literature database of in vitro (human cytosol/ S9/ hepatocytes) and in vivo (iv/oral) data collated for 22 AO substrates (total of 100 datapoints from multiple studies). Correction for unbound fraction in the incubation (fuinc) was done by experimental data or in silico predictions. The fraction metabolized by AO (fmAO) determined via in vitro/in vivo approaches was found to be highly variable. The geometric mean fold errors (gmfe) for scaled CLint,u (mL/min/kg) were 10.4 for human hepatocytes, 5.6 for human liver cytosols, and 5.0 for human liver S9, respectively. Application of these gmfe9s as empirical scaling factors improved predictions (45-57% within 2-fold of observed) compared with no correction (11-27% within 2-fold), with the scaling factors qualified by leave-one-out cross-validation. A road map for quantitative translation was then proposed following a critical evaluation on the in vitro and clinical methodology to estimate in vivo fmAO. In conclusion, the study provides the most robust system-specific empirical scaling factors to-date as a pragmatic approach for the prediction of in vivo CLint,u,AO in the early stages of drug development. Significance Statement Confidence remains low when predicting in vivo clearance of aldehyde oxidase (AO) substrates using in vitro systems, leading to de-prioritisation of AO substrates from the drug development pipeline to mitigate risk of unexpected and costly in vivo impact. The current study establishes a set of empirical scaling factors as a pragmatic tool to improve predictability of in vivo AO clearance. Developing clinical pharmacology strategies for AO substrates by utilizing mass balance/clinical DDI data will help build confidence in fmAO.

23 October 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
NINihan Izat
Nihan Izat
JBJayaprakasam Bolleddula
Jayaprakasam Bolleddula
PCPasquale Carione
Pasquale Carione
LVLeticia Huertas Valentin
Leticia Huertas Valentin
RJRobert S. Jones
Robert S. Jones
DSDaniel Scotcher
Daniel Scotcher
Aldehyde oxidase (AO) contributes to the clearance of many approved and investigational small molecule drugs, which are often dual substrates of AO and drug‐metabolizing enzymes such as cytochrome P450s (CYPs). As such, the lack of established framework for quantitative translation of the clinical pharmacologic correlates of AO‐mediated clearance represents an unmet need. This study aimed to evaluate the utility of physiologically based pharmacokinetic (PBPK) modeling in the development of AO and dual AO‐CYP substrates. PBPK models were developed for capmatinib, idelalisib, lenvatinib, zaleplon, ziprasidone, and zoniporide, incorporating in vitro functional data from human liver subcellular fractions and human hepatocytes. Prediction of metabolic elimination with/without the additional empirical scaling factors (ESFs) was assessed. Clinical pharmacokinetics, human mass balance, and drug–drug interaction (DDI) studies with CYP3A4 modulators, where available, were used to refine/verify the models. Due to the lack of clinically significant AO‐DDIs with known AO inhibitors, the fraction metabolized by AO (fmAO) was verified indirectly. Clearance predictions were improved by using ESFs (GMFE ≤1.4‐fold versus up to fivefold with physiologically‐based scaling only). Observed fmi from mass balance studies were crucial for model verification/refinement, as illustrated by capmatinib, where the fmAO (40%) was otherwise underpredicted up to fourfold. Subsequently, independent DDI studies with ketoconazole, itraconazole, rifampicin, and carbamazepine verified the fmCYP3A4, with predicted ratios of the area under the concentration–time curve (AUCR) within 1.5‐fold of the observations. In conclusion, this study provides a novel PBPK‐based framework for predicting AO‐mediated pharmacokinetics and quantitative assessment of clinical DDI risks for dual AO‐CYP substrates within a totality‐of‐evidence approach.

28 January 2021 in Biopharmaceutics & Drug Disposition
Verified
Journal Article
Closed access
PDF file
NINihan Izat
Nihan Izat
SSSelma Sahin
Selma Sahin

1 January 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
HAH. Asci
H. Asci
MSMehtap Savran
Mehtap Savran
FCF. Cengiz Callıoglu
F. Cengiz Callıoglu
SSS. Sahin
S. Sahin
NHN. Hasseyid
N. Hasseyid
HGH. Kesici Guler
H. Kesici Guler